Research overview: adjuvanted versus recombinant feline vaccines

Concerns about injection-site sarcomas and inflammation spurred development of non-adjuvanted recombinant feline vaccines, such as canarypox-vectored products, intended to provoke less local inflammation than traditional adjuvanted vaccines while maintaining immunogenicity. Debate continues over the relative safety and duration of immunity of different vaccine technologies. This overview compiles the vaccinology literature rather than one citation, describing how adjuvants enhance immune response but may increase local reactions, why vectored and non-adjuvanted options were pursued for feline safety, and how clinicians weigh efficacy, duration, and adverse-event risk in vaccine selection. It matters because vaccine technology choices in cats are shaped uniquely by the injection-site sarcoma phenomenon, making the cat a notable case study in balancing immunization benefits against rare but serious adverse effects.